Compare FTF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTF | CRBP |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.2M | 190.3M |
| IPO Year | 2003 | 2014 |
| Metric | FTF | CRBP |
|---|---|---|
| Price | $5.43 | $4.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $34.89 |
| AVG Volume (30 Days) | 252.8K | ★ 860.0K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $131.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $5.27 | $3.87 |
| 52 Week High | $6.29 | $12.88 |
| Indicator | FTF | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 24.93 |
| Support Level | $5.29 | N/A |
| Resistance Level | $5.89 | $8.13 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 92.11 | 21.58 |
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective, is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.